

AMENDMENTS TO THE CLAIMS

This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

1. (currently amended) A [[M]]monoclonal antibody directed against an epitope within the 30 most N-terminal amino acids of the Col1 domain of human PIIINP, wherein the sequence of the 30 most N-terminal amino acids is Gln-Glu-Ala-Val-Glu-Gly-Gly-Cys-Ser-His-Leu-Gly-Gln-Ser-Tyr-Ala-Asp-Arg-Asp-Val-Trp-Lys-Pro-Glu-Pro-Cys-Gln-Ile-Cys-Val.
2. (currently amended) The [[M]]monoclonal antibody according to claim 1, wherein the antibody is as described in 1[[.]] characterized by preferentially binding to trimeric PIIINP.
- 3-5. (canceled)
6. (new) A monoclonal antibody produced from a cell line identified as mAb 35J22.
7. (new) A monoclonal antibody produced from a cell line identified as mAb 35J23.
8. (new) A sandwich immunoassay product comprising a monoclonal antibody bound to a support and a second antibody that recognizes trimeric PIIINP, wherein said monoclonal antibody is directed against an epitope within the 30 most N-terminal amino acids of the Col1 domain of human PIIINP, the sequence of the 30 most N-terminal amino acids being Gln-Glu-Ala-Val-Glu-Gly-Gly-Cys-Ser-His-Leu-Gly-Gln-Ser-Tyr-Ala-Asp-Arg-Asp-Val-Trp-Lys-Pro-Glu-Pro-Cys-Gln-Ile-Cys-Val..
9. (new) A sandwich immunoassay product comprising a monoclonal antibody bound to a support and a second antibody that recognizes trimeric PIIINP, wherein the monoclonal antibody is produced from a cell line identified as mAb 35J22.
10. (new) The immunoassay according to claims 8 or 9, wherein the second antibody comprises a detectable label.